Navigation Links
Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008
Date:11/18/2008

MALVERN, Pa., Nov. 18 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that over $10 million of CSL Behring's Privigen was sold in the U.S. during the third quarter of 2008. Privigen is the newest brand of intravenous immune globulin (IVIG) and was launched in the first quarter of 2008. IVIG is a product created from the blood plasma of thousands of donors and is used to treat immune deficiencies, inflammatory and autoimmune diseases, acute infections and various other diseases.

The newly released edition of the IVIG Market Guide (U.S.) also finds that Baxter sold more grams of IVIG to hospitals than any other company in the U.S. during the third quarter of 2008. Baxter is currently the leader in hospital sales of IVIG.

"Based on recent news, if CSL Behring acquires Talecris, CSL Behring's market share of IVIG will increase significantly and could potentially surpass Baxter as the leader in hospital sales of IVIG," added Matthew W. Mahr, Pharm.D., M.B.A., analyst at AMR.

Why Pharmaceutical Companies Need this Information

The IVIG Market Guide (U.S.) enables pharmaceutical companies to monitor hospital utilization rates of intravenous immune globulin products. The data captured in this audit reveals usage by indication, dosing, ordering physician specialty and patient demographics for recipients of this group of products.

About The IVIG Market Guide (U.S.)

The IVIG Market Guide (U.S.) is the industry's most comprehensive market research study of IVIG. This product has two separate components including The IVIG Hospital Patient Profile Reports and The IVIG Hospital Purchasing Audit. The purchasing audit provides IVIG product market shares (in grams and dollars) and is produced twice a year. The patient profile report identifies relative usage patterns by indication, patient demographics, prescribing physician, dosing and insurance coverage and is produced once a year.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales               Elizabeth Marshall
    Decision Resources            Decision Resources, Inc.
    781-296-2691                  781-296-2563
    nmorales@dresources.com       emarshall@dresources.com


'/>"/>
SOURCE Arlington Medical Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. Atritech Announces Completion of a $22 Million Equity Financing
3. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
4. EntreMed Raises $20 Million to Support Clinical Development Program
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
7. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
8. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
9. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
10. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
11. 38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):